替米沙坦治疗非酒精性脂肪性肝纤维化的临床研究  

作　　者：沈毅慧[1] 夏冬[1] 迟洪霞[1] 刘小娟[1] 安冀坤 刘江奎[1] 

机构地区：[1]华北石油管理局总医院消化内科,河北任丘062552 [2]华北石油管理局总医院儿科,河北任丘062552

出　　处：《世界中医药》2016年第B03期562-563,共2页World Chinese Medicine

摘　　要：目的观察替米沙坦治疗非酒精性脂肪性肝纤维化的疗效。方法：将86例非酒精性脂肪性肝炎患者随机分为两组。两组均给予改善生活方式，控制体重的治疗，在此基础上，治疗组50例给予替米沙坦口服，对照组36例给予维生素E口服，均治疗6个月。结果：两组患者治疗后，一般情况均有改善。治疗组患者治疗前后比较，ALT、TG、血糖、体质指数（BMI）、肝纤维化谱及肝脏B超均显示肝脏纤维化程度明显减轻，差异有显著性（P〈0．05）。治疗组与对照组治疗后比较肝纤维化程度明显改善，差异有显著性（P〈0．05）。结论：替米沙坦能改善糖脂代谢，减轻体重，改善非酒精性脂肪性肝炎患者的纤维化，值得在临床推广应用。Objective：Efficacy of telmisartan in treatment of non-alcoholic fatty liver fibrosis. Methods：86 patients with non-alcoholic steatohepatitis patients were randomly divided into two groups. Both groups were given improvement of lifestyles and weight control,while 50 cases in treatment group treated with telmisartan,, 36 cases in the control group were given vitamin E orally. The period of treatment was 6 months.Results：The general situations were all improved in the two groups after treatment. Comparison of treatment groups before and after the treatment, ALT, TG, blood glucose, body mass index （BMI）, hepatic fibrosis and liver B ultrasound spectrum Showed the degree of liver fibrosis was significantly reduced, the difference was significant （P〈0.05）. The treatment group compared with the control group after treatment, the degree of liver fibrosis improved obviously, the difference was significant （P〈0.05）. Conclusion：Telmisartan can improve glucose and lipid metabolism, reduce weidat, improve fibrosis in patients with nonalcoholic steatoheDatitis, and worth spreadinz clinically.

关 键 词：替米沙坦 非酒精性脂肪性肝炎 肝纤维化 

分 类 号：R575.5[医药卫生—消化系统]